Lupus Drug Fails, PTV News: Apr 22, 2010




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Lupus Drug Fails, PTV News: Apr 22, 2010
Released on: April 22, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
Human Genome Sciences’ Benlysta fails to meet secondary goals.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Kevin Bottomley
Head of Transactions
PharmaVentures

Kevin is an experienced business development specialist, with over 25 years of experience in pharmaceutical and biotechnology companies involving senior positions in research, alliance management and business development. He has a proven track record of successful deal-making having worked at Roche, Quintiles, Hoechst (Sanofi-Aventis) and at Inpharmatica, where from 2001 to 2006 he was a Senior Director of Business Development. Kevin has a degree in Pharmacology from Kings College, University of London.
Human Genome Sciences (HGS)
Human Genome Sciences is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs." The company focuses on drug development, as well as drug discovery and currently (as of 2008) has a pipeline of novel compounds in clinical development, including drugs to treat such diseases as hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. It has historically pursued collaborations with other biotechnology and pharmaceutical companies, for development partnerships and technology licensing.